Four Indian generic companies (Cipla, Emcure, Hetero and NATCO) takes sub-licenses from Medicines Patent pool (MPP) on Daclatasvir. The copy of the sub- licenses are not available yet, but please refer to the form for an outline. Long term implications of how this improves access in included territory or inhibits ...
January 22, 2016admin
A study on how generic competition can rapidly lower the prices of drugs with high hepatitis C cure rates, like sofosbuvir and daclatasvir and help achieve global treatment scale-up, 12th January, 2016 Click here for more details.
January 18, 2016admin
Pricing/manufacturer/marketer details for the Indian generic ledipasvir and sofosbuvir co-formulated tablets as on 10th January 2016. Click here to see the full list.
January 11, 2016admin
6 October 2015, Bangkok, Hanoi and Kuala Lumpur The Asia Pacific Network of People living with HIV/AIDS (APN+), Positive Malaysian Treatment Access & Advocacy Group (MTAAG+) and the Vietnam Network of People living with HIV (VNP+) are expressing deep dismay at news of the conclusion of the Trans-Pacific Partnership Agreement (TPP) ...
October 7, 2015admin
October 6, 2015admin
Numbers of patient groups and CSOs working on Hepatitis C in Asia requested Indian Government to issue a waiver for requirement to have clinical trial on the coming generic DAAs as they had done during Sofosbuvir registration process back in December 2014, click here to read the full letter.
September 28, 2015admin
10 September 2015 The latest compilation of availability and pricing of generic Sofosbuvir in India , click here to see full document
September 11, 2015admin
A summarized information of patents on sofosbuvir, ledipasvir and daclatasvir in parts of South and south-east Asia. The documents also covers situation of registration of these medications in the countries as on August 2015..read full document
September 9, 2015admin
Bangkok 11 August 2015 TREAT Asia just published an overview documentation on Sofosbuvir, the snapshot provides a brief summary of the medication, its regulatory approvals, treatment response data from early clinical trials and pricing information. Click here to see the full document
August 11, 2015admin
Hepatitis C Treatment Without Borders is a social media page dedicated to spread hepatitis C information and mobilize social action. Bounded together in solidarity to help access equitable access to life-saving drugs and to provide hope and optimism to a world where human suffering takes second place to corporate greed ...
July 23, 2015admin